Tamtam Try Tamtam free
Insel Gruppe logo

Insel Gruppe account plan

Medical care system in Switzerland

At a glance

Insel Gruppe is the Bern university hospital group (Inselspital), one of Switzerland's largest care organisations, back to a CHF 134.8 million profit in 2025.

Insel Gruppe is a university hospital group in Bern, Switzerland, made up of the Inselspital university hospital, the rural hospitals Aarberg, Belp and Riggisberg and the Berner Reha Zentrum in Heiligenschwendi; it provides highly specialised medicine and basic care and works closely with the University of Bern. In 2025 group operating income after consolidation was CHF 1,999,192 thousand, EBITDA CHF 279.9 million (14.0 % margin) and group profit CHF 134.8 million, after losses every year since 2021. It treated 55 802 acute inpatients and 893 207 outpatient consultations and employed 8 726 full-time equivalents at end 2025. The foundation Inselspital-Stiftung heads the group, and the Canton of Bern owns the rural hospital real estate company; the group is the largest private employer of the region.

Business units

Strategic priorities

Strategie 2035
Adopted on 13 June 2025, the strategy aims to make Insel Gruppe a pioneer of digital and translational medicine, with five fields of action: staff and culture, patient orientation, medicine of the future, market positioning and networking, and economic efficiency.
Reorganisation along patient pathways
For 2027 the ten medical divisions will be merged into four larger organisational units to promote interprofessional work along patient pathways.
Data-based medicine and AI
Strategie 2035 calls for responsible use of health data and artificial intelligence and for developing the Insel-Campus as a centre of translation, with neurosciences, cardiovascular and oncology as current priorities.
Outpatient shift
The group wants to actively promote outpatient care and bundle it organisationally and spatially, as the new TARDOC and outpatient flat-rate tariffs and EFAS push care toward outpatient settings.
Sustaining the margin and staff culture
Strategie 2035 sets an explicit margin and self-financing goal, while the chair and CEO both put staff motivation and retention at the centre after troubled years.

Latest results

In the first half of 2026 group profit was CHF 41.9 million against CHF 26.3 million a year earlier, and EBITDA CHF 108.2 million (10.7 % margin). Hospital operations income rose 3.6 % to CHF 1 007.9 million, with outpatient income up 7.4 % to CHF 285.0 million and inpatient income up 1.3 % to CHF 582.8 million. The switch to the new TARDOC outpatient tariff on 1 January 2026 delayed invoicing, pushing operating cash flow to CHF -145.1 million and cash down to CHF 231.5 million. The group gives no numerical guidance and says the pace of change remains high.

Investments and deals

Epic clinical information system
Introduced in March 2024 to replace more than 50 systems, Epic's project costs total CHF 182.5 million; the chair credits it with efficiency gains such as online appointment booking and fewer no-shows.
Marie-Colinet-Haus renovation
2025 investment centred on the Marie-Colinet-Haus (CHF 71.3 million), which opened in mid-2026 for gynaecology and obstetrics, neonatology and ophthalmology.
Anna-Seiler-Haus main building
The new main building opened in summer 2023 and is credited with better processes; the old Bettenhochhaus carries a demolition provision.
Bond financing
The group had CHF 910 million of bonds at end 2025, including two Green Bonds; a CHF 250 million bond was repaid or refinanced in H1 2026.

Challenges and risks

New outpatient tariff system
Converting billing to TARDOC and outpatient flat rates raised accrued income by CHF 227.1 million in H1 2026 and required more short-term debt; a further version of the tariff is due on 1 January 2027.
Tariff disputes
The dispute with the HSK purchasing group over the 2022 and 2023 inpatient base rate is before the Federal Administrative Court, and there is no 2026 outpatient agreement with the ZMT.
Regulatory uncertainty
The KVV revision, EFAS and the second stage of the nursing initiative are pending and their financial effects cannot yet be fully estimated.
Workload and skills shortage
The CEO says workload has increased and the group must create an environment where people stay, after years in which staff spoke of bullying and a climate of fear.
Rising medical supply costs
Medical supplies rose 10.8 % in 2025, driven by drugs, implants and prostheses.

What leadership says

“Wir müssen ein Umfeld schaffen, in dem die Leute gerne arbeiten und bei uns bleiben.”

Jennifer Diedler, Chair of the Executive Board (CEO) · SRF interview, 2026-05-06 (We must create an environment where people like to work and stay with us)

“Ein offener Diskurs, fernab von Hierarchien, ist entscheidend.”

Jennifer Diedler, Chair of the Executive Board (CEO) · SRF interview, 2026-05-06 (Open discourse, away from hierarchies, is decisive)

“Auch andere Abläufe sind mit Epic viel effizienter geworden”

Adrian Schmitter, Chair of the Board of Directors · SRF report on the 2025 results, 2026-03-03 (other processes have also become much more efficient with Epic)

“Wir müssen das Personal motivieren.”

Adrian Schmitter, Chair of the Board of Directors · SRF report on the 2025 results, 2026-03-03 (We must motivate the staff)

Where a supplier can help

Outpatient billing and coding
The TARDOC conversion that delayed invoicing and the coding backlog behind higher accrued revenue point to revenue cycle, coding and billing process support.
Epic-adjacent digital tools
With Epic in place and Strategie 2035 calling for data-based medicine and AI, suppliers of analytics, AI and integrations around the clinical system fit the medicine-of-the-future priority.
Workforce retention and culture
The CEO and chair's focus on staff motivation and the skills shortage open room for workforce management, rostering, leadership development and employee experience offers.
Patient pathway and outpatient processes
Merging ten divisions into four units along patient pathways and bundling outpatient care call for process consulting, patient flow and scheduling tools.
Medical supply procurement
Medical supply costs rising 10.8 % against an explicit margin goal make procurement, implants and drug cost management relevant.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Insel Gruppe?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Insel Gruppe

What is Insel Gruppe?

Insel Gruppe is the university hospital group of Bern, Switzerland, comprising the Inselspital, the rural hospitals Aarberg, Belp and Riggisberg and the Berner Reha Zentrum.

What is Insel Gruppe's revenue and profit?

In 2025 group operating income was CHF 1,999,192 thousand and group profit CHF 134.8 million, a return to profit after losses each year since 2021. H1 2026 profit was CHF 41.9 million.

How many employees does Insel Gruppe have?

Insel Gruppe had 8 726 full-time equivalents at the end of 2025 and is the largest private employer of the region.

Who leads Insel Gruppe?

Prof. Jennifer Diedler has chaired the executive board since the start of 2026, and Adrian Schmitter has chaired the board of directors since November 2025.

What is Insel Gruppe's strategy?

Strategie 2035 positions the group as a pioneer of digital and translational medicine, focusing on staff culture, patient orientation, medicine of the future, networking and economic efficiency.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)